Biogen Inc vs Hyatt Hotels Corporation — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Hyatt Hotels Corporation trades at $171.54 (market cap $16.27B). The key difference: Biogen Inc is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | H | |
|---|---|---|
Market Cap | $30.13B | $16.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $202.09 |
52-Week Low | $128.93 | $135.42 |
Enterprise Value | $37.20B | $20.17B |
Dividend Yield | — | 0.35% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →